Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2016-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2016年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2016 年半年度报告摘要' which translates to '2016 Semi-Annual Report Summary'. It contains detailed financial data for the first half of 2016, including total assets, net profit, cash flow, revenue, and segment analysis. It also includes management discussion and analysis of business operations, industry trends, and future plans. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. The content matches the characteristics of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with comprehensive financial and operational information. Therefore, the appropriate classification is 'IR'. H1 2016
2016-08-18 Chinese
七届十四次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement regarding the 2016 semi-annual report of 哈药集团股份有限公司. It includes the supervisory board's review and approval of the 2016 half-year report, confirming compliance with laws and regulations, and the accuracy and completeness of the report. The document is relatively short (643 characters) and serves as an official announcement of the supervisory board's resolution and opinion on the half-year report, rather than the report itself. Therefore, it is not the interim/quarterly report (IR) itself but an announcement related to it. Given the nature of the content, it fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement about the supervisory board's resolution and opinion on the half-year report, not the report itself.
2016-08-18 Chinese
2016年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2016 年半年度报告" which translates to "2016 Semi-Annual Report." It contains detailed financial data, accounting data, financial indicators, management discussion and analysis, business overview, and operational plans for the first half of 2016. The document includes comprehensive financial statements and analysis for the period January 1, 2016 to June 30, 2016, which fits the definition of an Interim / Quarterly Report (IR). The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2016
2016-08-18 Chinese
关于聘任证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors regarding the appointment of a securities affairs representative. It includes details about the individual's background and contact information. There is no financial data, report, or presentation included. The document is a management or board announcement about personnel changes, specifically related to the securities affairs representative role. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a regulatory filing of financial data.
2016-08-18 Chinese
关于下属公司获得《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding its subsidiary 哈药集团制药六厂 receiving a Drug GMP Certificate issued by the Heilongjiang Food and Drug Administration. It details the certificate number, validity, production lines, product market information, and impact on the listed company. The document is short (1099 characters) and serves as a formal public announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory certificate. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-08-18 Chinese
关于换领“四证合一”营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the company's replacement of multiple business licenses with a unified business license under a regulatory reform. It contains no financial data, no mention of financial results, no management discussion, no voting results, no legal proceedings, and no detailed report content. The document is an official announcement about a regulatory or administrative change related to the company's business license. It is very short (373 characters) and does not contain any report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-08-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.